USMD
Irving
About USMD
USMD Holdings, Inc. (NASDAQ:USMD) is an innovative, integrated health system, led by physicians rather than third-party entities, committed to maintaining the vital doctor-patient relationship, ensuring better quality and more affordable care to patients. A business combination comprised of USMD Inc. (“USMD”), Urology Associates of North Texas, L.L.P. (“UANT”), Medical Clinic of North Texas, P.A. (“MCNT”), and IMPEL Management Services, L.L.C., it provides world-class, state-of-the-art healthcare. USMD develops, operates, and manages entities that deliver diagnostic, therapeutic, and hospital-based healthcare to patients. UANT is a physician group practice that provides professional medical services in the medical specialty of urology. MCNT is a multi-specialty physician practice group that provides medical services to patients throughout the Dallas/Fort Worth metropolitan area. IMPEL provides management and consulting services to physician practices nationally. USMD began in 1994 with the creation of US Lithotripsy and has grown and expanded its services to include: twenty-three lithotripsy partnerships nationwide, two general acute care hospitals in the Dallas-Fort Worth area, a CyberKnife facility in Fort Worth, Texas and ten cancer treatment centers nation-wide. It currently serves the DFW metroplex with 240 physicians and associate practitioners, and provides healthcare services to patients across 18 different specialties at its hospitals, cancer treatment centers and physician clinics. USMD’s Corporate Headquarters is located in Las Colinas (Irving), Texas.
Company Facts
- Operating status: Active
- Company type: For Profit
- IPO status: Delisted
- Employees: 1,001 – 5,000
- Total funding: $980.0K
- Funding stage: M&A
- Last round: Seed (Aug 2012)
- Ticker: nasdaq:USMD
- Website: usmdinc.com
- Phone: 2144934000
Industries & Categories
Biotechnology, Health Care, Pharmaceutical, Therapeutics
Social Profiles
Canonical: https://fsome.com/organization/usmd-3144580 · For the full interactive profile (charts, investors, team, acquisitions, press), please enable JavaScript.